Abeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016

Company CEO and VP of Patient Advocacy to Present on Wednesday, November 16 at 11:30 am & 17:00 pm CET

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 11/15/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, PhD, presenting and VP of Patient Advocacy, Michelle Berg, moderating a panel discussion for the Company at the World Orphan and Drug Congress Europe 2016.

The following are the specific details regarding Abeona Therapeutics Presentation:

Event: Expectation Setting and Education on Gene Therapies for Orphan Diseases
Moderator: VP of Patient Advocacy, Michelle Berg
Date: Wednesday, November 16, 2016
Presentation Time: 11:30 am CET
Location: Brussels -- Europe

Event: Translating a Potential Gene Therapy for a Rare Disease into Clinical Trial
Speaker: President and CEO, Timothy J. Miller, PhD
Date: Wednesday, November 16, 2016
Presentation Time: 17:00 pm CET
Location: Brussels -- Europe

Abeona Recent Highlights:

• November 1, 2016: Abeona announced closing of its $42 million underwritten offering of common stock
• October 25, 2016: Abeona announced receipt of Fast Track designation from the FDA for ABO-102
• October 18, 2016: Abeona received Orphan Drug Designation in the European Union for ABO-102 gene therapy in Sanfilippo syndrome Type A
  
• October 14, 2016: Abeona presented top-line data of low-dose cohort for ABO-102 in Phase 1/2 clinical trial for MPS IIIA patients at Orphan Drugs and Rare Disease Congress October 19-20th in London, UK
  • ABO-102 reduced GAG (heparan sulfate) in urine 57.6% +/- 8.2%
  • ABO-102 reduced GAG (heparan sulfate) in the CSF 25.6% +/- 0.8%
  • Reduction in liver volume of 17.7% +/- 1.9%
  • Reduction in spleen volume of 17.6% +/- 7.1%
• October 7, 2016: Abeona announced JAMA publication of preclinical data supporting clinical translation of Juvenile Batten Disease gene therapy
• October 5, 2016: Abeona announced Data Safety Monitoring Board approved ABO-102 dose escalation for second cohort in a Phase 1/2 Clinical Trial for Sanfilippo syndrome Type A
• September 26, 2016: Abeona enrolled first patient in Phase 2 for EB-101, gene therapy clinical trial for epidermolysis bullosa
• September 21, 2016: Abeona announced the exclusive worldwide license of the AIM™ AAV capsid portfolio for next generation gene therapies from University of North Carolina at Chapel Hill
• September 8, 2016: Abeona enrolled 5^th patient in Phase 1 gene therapy clinical trial for epidermolysis bullosa

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and plasma-based therapies for life-threatening rare genetic diseases. Abeona's lead programs are ABO- 102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Investor Contact:
Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com

Media Contact:
Andre'a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc
+1 (212)-786-6208
alucca@abeonatherapeutics.com

Source: Abeona Therapeutics Inc.

Released November 15, 2016